MIAMI- The Centers for Disease Control and Prevention (CDC) has been notified of a voluntary recall of over-the-counter oxymetazoline HCl 0.05 percent nasal spray because of intrinsic contamination with Burkholderia cepacia complex. The nasal spray is distributed as "Major Twice-A-Day 12 Hour Nasal Spray." The manufacturer, Propharma Inc., of Miami, has recalled lot No. K4496, released in November 2003, with an expiration date of October 2006.
Preliminary molecular epidemiology indicates that isolates related to the strain found in the nasal spray have been recovered from patients in multiple states. Clinicians should be aware that patients using product from this lot number might have been exposed to B. cepacia complex. Patients with underlying lung disease (especially cystic fibrosis) might be at increased risk for severe infections with B. cepacia complex. Cases of B. cepacia complex infection or colonization associated with use of this product should be reported to the local or state health department and the CDC at (800) 893-0485.
Source: CDC
Reflecting on the US Withdrawal from the World Health Organization
January 21st 2025An infection preventionist reels from the US exit from WHO, writing that it disrupts global health efforts, weakens infection control, and lacks research funding and support for low-income nations dependent on WHO for health care resources.
Infections Do Not Recognize International Borders: The Potential Impact of US Withdrawal From WHO
January 21st 2025The US withdrawal from WHO jeopardizes infection prevention, research funding, and global collaboration, disproportionately impacting low-income nations reliant on WHO support for equitable health care advancements.
Infection Intel:EvaClean Expands Global Reach With Microsplitting Partnership
January 20th 2025EvaClean partners with Microsplitting Ltd. to distribute its advanced disinfection systems and absorbents, revolutionizing infection prevention across health care, education, hospitality, and industrial sectors worldwide.